Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19

Trial Profile

A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2020

At a glance

  • Drugs GSK 2586881 (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 27 Feb 2020 New trial record
    • 26 Feb 2020 According to an Apeiron Biologics media release, data from this trial will be assessed to ascertain whether a Phase 2B clinical trial in a larger number of patients is warranted.

Trial Overview

Purpose

This pilot investigator initiated randomized, unblinded dual-arm trial to evaluate the impact of rhACE2 on biological, physiologic, and clinical outcomes, as well as safety in patients with severe SARS-CoV-2 infection. Patients will be treated for seven days to obtain preliminary data. After seven days of treatment, the trial data will be evaluated and potential further clinical development will be assessed by APEIRON and the IIT team.

Comments

According to clinical.gov, trial was withdrawn, as there was no CDE approval for trial.

Primary Endpoints

Time course of body temperature (fever)

description: Compare the time course of body temperature (fever) between two groups over time.
time_frame: 14 days

Viral load over time

description: Compare viral load between two groups over time.
time_frame: 14 days

Other Endpoints

P/F ratio over time

description: PaO2/FiO2 ratio
time_frame: 14 days

Sequential organ failure assessment score(SOFA score) over time

description: SOFA, including assessment of respiratory, blood, liver, circulatory, nerve, kidney, from 0 to 4 scores in each systems, the higher scores mean a worse outcome.
time_frame: 14 days

Pulmonary Severity Index (PSI)

time_frame: 14 days

Image examination of chest over time

description: Based on radiologist's assessment of inflammatory exudative disease, category as follows: significant improvement, partial improvement, no improvement, increase of partial exudation, significant increase in exudation, unable to judge.
time_frame: 14 days

Proportion of subjects who progressed to critical illness or death

time_frame: 14 days

Time from first dose to conversion to normal or mild pneumonia

time_frame: 14 days

T-lymphocyte counts over time

time_frame: 14 days

C-reactive protein levels over time

time_frame: 14 days

Angiotensin II (Ang II) changes over time

time_frame: 14 days

Angiotensin 1-7 (Ang 1-7) changes over time

time_frame: 14 days

Angiotensin 1-5 (Ang 1-5) changes over time

time_frame: 14 days

Renin changes over time

time_frame: 14 days

Aldosterone changes over time

time_frame: 14 days

Angiotensin-converting enzyme (ACE) changes over time

time_frame: 14 days

Angiotensin-converting enzyme 2 (ACE2) changes over time

time_frame: 14 days

Interleukin 6 (IL-6) changes over time

time_frame: 14 days

Interleukin 8 (IL-8) changes over time

time_frame: 14 days

Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time

time_frame: 14 days

Plasminogen activator inhibitor type-1 (PAI-1) changes over time

time_frame: 14 days

Von willebrand factor (vWF) changes over time

time_frame: 14 days

Tumor necrosis factor-α (TNF-α) changes over time

time_frame: 14 days

Soluble receptor for advanced glycation end products (sRAGE) changes over time

time_frame: 14 days

Surfactant protein-D (SP-D) changes over time

time_frame: 14 days

Angiopoietin-2 changes over time

time_frame: 14 days

Frequency of adverse events and severe adverse events

time_frame: 14 days [1]

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Number

    Planned: 24

    Actual: 0

  • Sex male & female
  • Age Group 18-80 years; adult; elderly

Patient Inclusion Criteria

1. Laboratory diagnosis: - Respiratory specimen is positive for SARS-CoV-2 nucleic acid by RT-PCR; OR, - The viral gene sequencing of the respiratory specimen is highly homologous to known novel coronavirus. 2. Fever: Axillary temperature >37.3℃ 3. Respiratory variables (meets one of the following criteria): - Respiratory rate: RR ≥25 breaths/min - Oxygen saturation ≤93% at rest on room air - PaO2/FiO2 ≤300 mmHg1 mmHg=0.133 KPa - Pulmonary imaging showed that the lesions progressed more than 50% within 24-48 hours, and the patients were managed as severe 4. HBsAg negative, or HBV DNA ≤10^4 copy/ml if HBsAg positive; anti-HCV negative; HIV negative two weeks prior to signed Informed Consent Form (ICF) 5. Appropriate ethics approval and 6. ICF

Patient Exclusion Criteria

- Age <18 years; Age >80 years - Pregnant or breast feeding woman or with positive pregnancy test result - P/F <100 mmHg - Moribund condition (death likely in days) or not expected to survive for >7 days - Refusal by attending MD - Not hemodynamically stable in the preceding 4 hours (MAP ≤65 mmHg, or SAP <90 mmHg, DAP <60 mmHg, vasoactive agents are required) - Patient on invasive mechanical ventilation or ECMO - Patient in other therapeutic clinical trial within 30 days before ICF - Receive any other ACE inhibitors (ACEI), angiotensin-receptor blockers (ARB) treatment within 7 days before ICF - Chronic immunosuppression: current autoimmune diseases or patients who received immunotherapy within 30 days before ICF - Hematologic malignancy (lymphoma, leukemia, multiple myeloma) - Other patient characteristics (not thought to be related to underlying COVID-19) that portend a very poor prognosis (e.g, severe liver failure, and ect) - Known allergy to study drug or its ingredients related to renin-angiotensin system (RAS), or frequent and/or severe allergic reactions with multiple medications - Other uncontrolled diseases, as judged by investigators - Body weight ≥85 kg

Trial Details

Identifiers

Identifier Owner
NCT04287686 ClinicalTrials.gov: US National Institutes of Health
GIRH-APN01 -

Organisations

  • Affiliations Apeiron Biologics

Trial Dates

  • Initiation Dates

    Planned : 01 Feb 2020

  • Primary Completion Dates

    Planned : 01 Apr 2020

  • End Dates

    Planned : 01 Apr 2020

Other Details

  • Design open; parallel; prospective; randomised
  • Phase of Trial Phase II
  • Location China
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
GSK 2586881Primary Drug Intravenous
-

rhACE2 group

0.4 mg/kg IV BID for 7 days (unblinded) + standard of care
Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2) (In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.)

Control group

Standard of care; no placebo

Trial Centres

Investigators

Investigator Centre Name Trial Centre Country
Xinyun Yang, MD
020-83062338
gyfygcp@163.com
show details
GCP Office of The First Affiliated Hospital of Guangzhou Medical University China
Yimin Li, PhD, MD
+8613533569161
dryiminli@vip.163.com
show details
The First Affiliated Hospital of Guangzhou Medical University
-
Yonghao Xu, PhD, MD
+8613828409707
dryonghao@163.com
show details
-

Centres

Centre Name Location Trial Centre Country
-
-
-
GCP Office of The First Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong China
The First Affiliated Hospital of Guangzhou Medical University
-
-

Trial History

Event Date Event Type Comment
18 Mar 2020 Other trial event Last checked against ClinicalTrials.gov record. Updated 18 Mar 2020
15 Mar 2020 Status change - withdrawn prior to enrolment Status changed from not yet recruiting to withdrawn prior to enrolment. Updated 18 Mar 2020
04 Mar 2020 Other trial event New source identified and integrated (ClinicalTrials.gov record; NCT04287686) Updated 04 Mar 2020
27 Feb 2020 New trial record New trial record Updated 27 Feb 2020
26 Feb 2020 Other trial event According to an Apeiron Biologics media release, data from this trial will be assessed to ascertain whether a Phase 2B clinical trial in a larger number of patients is warranted. Updated 27 Feb 2020
26 Feb 2020 Other trial event According to an Apeiron Biologics media release,This trial cooperation has been supported by Dr. Liqun Zhang and team of Angalpharma Co., Ltd (Suzhou, China), for coordinating the Chinese clinical trial with the support of dMed Pharmaceutical Co., a CRO team based in China. Updated 27 Feb 2020
26 Feb 2020 Other trial event According to an Apeiron Biologics media release, this trial is being supported by by a global team of leading experts: Prof. Nanshan Zhong and Prof. Yimin Li, both of the Guangzhou Institute of Respiratory Health and leading physicians in fight against COVID-19 in China, will oversee the trial; and Prof. Josef Penninger, Scientific Director and Professor of the Life Science Institute of the University of British Columbia, Canada. Updated 27 Feb 2020
26 Feb 2020 Other trial event According to an Apeiron Biologics media release, this trial is being supported by by a global team of leading experts: Intensive care specialist, Prof. Arthur Slutsky, Scientist, St. Michael's Hospital, Toronto, and Prof. of Medicine, Surgery and Biomedical Engineering at the University of Toronto (Toronto, Canada) and Prof. Haibo Zhang, Prof. of Anesthesiology, St. Michael's Hospital, University of Toronto. Updated 27 Feb 2020
25 Feb 2020 Status change - not yet recruiting Status changed from planning to not yet recruiting. Updated 04 Mar 2020

References

  1. ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2016;.

    Available from: URL: http://clinicaltrials.gov
  2. Apeiron Biologics. APEIRON's respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China. Media-Rel 2020;.

    Media Release
Back to top